132 related articles for article (PubMed ID: 6089368)
1. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
Lecompte T; Joussemet M; Hainaut J
Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
[No Abstract] [Full Text] [Related]
2. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
[TBL] [Abstract][Full Text] [Related]
3. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
Gorman RR; Fitzpatrick FA; Miller OV
Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
[No Abstract] [Full Text] [Related]
4. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
Gresele P; Deckmyn H; Huybrechts E; Vermylen J
Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
6. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
7. 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor.
Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Heikes JE; Sprague PW; Antonaccio MJ
Prostaglandins; 1981 Aug; 22(2):295-307. PubMed ID: 6270744
[TBL] [Abstract][Full Text] [Related]
8. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
11. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
[TBL] [Abstract][Full Text] [Related]
12. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
Lancet; 1982 Nov; 2(8308):1156-7. PubMed ID: 6128469
[No Abstract] [Full Text] [Related]
13. Intrathoracic platelet accumulation in the guinea-pig induced by intravenous administration of arachidonic acid--effect of cyclooxygenase and thromboxane synthetase inhibitors.
Barrett PA; Butler KD; Shand RA; Wallis RB
Thromb Haemost; 1986 Dec; 56(3):311-7. PubMed ID: 3105107
[TBL] [Abstract][Full Text] [Related]
14. Alteration of platelet responses to metabolites of arachidonic acid by oral contraceptives.
Pan IQ; Hall ER; Wu KK
Br J Haematol; 1984 Oct; 58(2):317-23. PubMed ID: 6089860
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor.
Cerletti C; Rajtar G; Bertelé V; de Gaetano G
Thromb Haemost; 1984 Oct; 52(2):215. PubMed ID: 6441306
[No Abstract] [Full Text] [Related]
16. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.
Randall MJ; Parry MJ; Hawkeswood E; Cross PE; Dickinson RP
Thromb Res; 1981 Jul 1-15; 23(1-2):145-62. PubMed ID: 6795753
[No Abstract] [Full Text] [Related]
17. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
Sills T; Heptinstall S
Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.
Patscheke H
Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP.
Bushfield M; McNicol A; MacIntyre DE
Biochem J; 1985 Nov; 232(1):267-71. PubMed ID: 3002327
[TBL] [Abstract][Full Text] [Related]
20. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
